Precision Equipment for the Assessment
and Treatment of Retinal Diseases
Two CE-marked medical devices serving the clinical and research sectors.
retinaWISE is an advanced chromatic pupillometer to assess photoreceptor functionality.
retinaSEES is a non-invasive multimodal laser platform for dry AMD.
retinaWISE
Chromatic pupillometry for objective retinal function
assessment.
retinaSEES
Delivers photothermal and photobiological stimulation
to treat intermediate dry AMD.
From Assessment to Treatment
Oculox combines objective assessment of retinal function with precision laser-based therapy.
retinaWISE
Chromatic Pupillometry
Non-invasive objective measurement of photoreceptor-mediated pupil reflex to anticipate morphological deviation through early functional changes.
View retinaWISE
retinaSEES
Precision Multimodal Laser Therapy
Advanced retinal tissue stimulation designed to help prevent AMD progression and preserve visual function for the intermediate pathological stage.
View retinaSEESOur Vision & Mission
One Platform to Manage a Chronic Degenerative Pathology
Vision Eradicate the onset of chronic degenerative disorders by preventive healthcare measures.
Mission Committed to developing solutions at the forefront of translational science, providing solid procedures to operators and patients to drive best clinical practices.
A Step-by-Step Process
01 · Anticipate
Evaluating Function
02 · Measure
Plan Preventive Actions
03 · Treat
Evidence-Based Therapy
04 · Assess
Evaluate Clinical Outcomes
Progressive pathologies require all four (APTA). Our goal is to deliver end‑to‑end disease management, from diagnosis through treatment and follow‑up.
Trusted by Clinicians and Researchers
Both retinaWISE and retinaSEES are used in research and clinical settings. Partnerships with KOLs, universities, and early adopters are growing their presence in hospitals and private practices.
Research Behind the Technology
The development and the results obtained with our medical devices have been described in peer-reviewed scientific publications.
Development of Multi-Mode Retinal Phototherapy Device
Technical introduction of retinaSEES. The multimodal laser has been engineered as a medical device able to deliver precise therapy.
IEEE I2MTC 2024
View publicationDevelopment of an Innovative Pupillometer Able to Selectively Stimulate the Eye's Fundus Photoreceptor Cells
Peer-reviewed validation of retinaWISE demonstrating selective photoreceptor stimulation via silent substitution and Maxwellian optics.
Diagnostics (Basel)
View publicationInvestigating Light Sensitivity in Bipolar Disorder (HELIOS-BD)
Clinical study protocol applying chromatic pupillometry to assess melanopsin pathway function in bipolar disorder patients on and off lithium therapy.
Wellcome Open Research
View publicationLatest News & Insights
First Italian Clinical Installations of retinaSEES-1.0 Announced
retinaSEES-1.0 is set to be installed at Studio Oculistico Dott. Vezzola in Salò and Corbetta, the first clinical deployments in Italy.
Read moreretinaSEES Receives CE Mark, Class IIb
retinaSEES has been certified as a CE-marked Class IIb medical device, meeting stringent EU regulatory requirements for safe clinical use.
Read morePartnership with Miloftalmica to Expand in the Italian Market
Oculox announces a new distribution partnership with Miloftalmica, expanding access to retinaWISE and retinaSEES across Italy's ophthalmology market.
Read moreWhere to Meet Us
ICOVS 2026
Visit our poster presentation to learn about our latest research findings.
Read more
Pupil Colloquium
Meet our team at our booth. Details coming soon.
Read more
SLRCH
Oculox is a sponsor of the SLRCH meeting, with a booth presence focused on chromatic light science.
Read more
EURETINA 2026
Meet our team at the annual congress of the European Society of Retina Specialists.
Read more
EVER 2026
Join us at the Pupil Symposium, organised together with Prof. Barbur.
Read more
Eyenovate
Catch our invited talk at Eyenovate, the FLORetina start-up innovation programme.
Read more
FLORetina 2026
Meet us at one of Europe’s leading retinal meetings, alongside our partners.
Read moreGet in Touch
Talk to the Oculox Team
Whether you are an ophthalmologist exploring clinical use, a researcher interested in collaboration, or a distributor seeking partnership, we would like to hear from you.
Contact usOr write directly to info@oculox.com
Disclaimer
retinaWISE is a CE-marked Class I medical device, and retinaSEES is a CE-marked Class IIb medical device. They are not FDA-approved for clinical use in the United States.